Rivastigmine Transdermal System Patch, Extended Release
Product Images NDC 72162-1609

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Rivastigmine Transdermal System (NDC 72162-1609). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721621609)

Label for Rivastigmine Transdermal System 9.5 mg/24 hours patch by Bryant Ranch Prepack. Contains 30 extended-release transdermal patches with 18 mg rivastigmine base each, delivering 9.5 mg per 24 hours. Stored at 25°C with temperature excursion instructions. Manufactured by AdhexPharma. Includes two QR codes for dosage and administration instructions.*

FDA Label Image

Chemical Structure (Rivastigmine 01)

Chemical structure of rivastigmine, the active ingredient in Rivastigmine Transdermal System 9.5 mg/24h patch, shown as a molecular diagram with labeled functional groups and bonds.*

FDA Label Image

Figure 1 (Rivastigmine 02)

An illustration diagram showing a cross-sectional view of a multilayer transdermal patch system with four labeled layers and two highlighted dimples on the bottom layer.*

FDA Label Image

Figure 2 (Rivastigmine 03)

A line graph depicting rivastigmine plasma concentration (ng/mL) over 24 hours for three different dosages of a transdermal system: 4.6 mg/24h, 9.5 mg/24h, and 13.3 mg/24h. The x-axis represents time in hours, and the y-axis shows rivastigmine concentration with error bars indicating variability. Higher doses show higher plasma levels with peak concentrations occurring before 12 hours.*

FDA Label Image

Figure 3 (Rivastigmine 04)

Line graph showing least square mean changes from baseline ADAS-Cog rating over 24 weeks during treatment. Four groups are compared: 17.4 mg/24 hours and 9.5 mg/24 hours doses of Rivastigmine transdermal system, capsules 6 mg BID, and placebo. The y-axis indicates clinical improvement and decline, and the x-axis shows weeks of treatment.*

FDA Label Image

Figure 4 (Rivastigmine 05)

A bar chart displaying the percentage of patients according to ADCS-CGIC (Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change) ratings. The chart compares four groups: 17.4 mg/24 hours, 9.5 mg/24 hours, capsules 6 mg BID, and placebo, across categories from 'Markedly Improved' to 'Markedly Worse.'*

FDA Label Image

Figure 5 (Rivastigmine 06)

A line graph showing ADCS-ADL change from baseline (LS means SEM) over 48 weeks of treatment. It compares two Rivastigmine Transdermal System strengths: 13.3 mg/24hr (solid line with squares) and 9.5 mg/24hr (dotted line with diamonds). The vertical axis ranges from clinical improvement to clinical decline, while the horizontal axis indicates weeks of treatment from 0 to 52.*

FDA Label Image

Figure 6 (Rivastigmine 07)

A line graph depicting the change from baseline in ADAS-Cog scores over 52 weeks of treatment for Rivastigmine Transdermal Systems at 9.5 mg/24h and 13.3 mg/24h doses. The graph shows clinical improvement and decline with a vertical axis indicating least squares means and standard error of the mean, and a horizontal axis representing weeks of treatment. Data points include error bars.*

FDA Label Image

Figure 7 (Rivastigmine 08)

A line graph comparing the LS mean change over 24 weeks of treatment between Rivastigmine Transdermal System 15 cm² and 5 cm² patches, showing clinical improvement versus clinical decline. The graph includes p-values and confidence intervals for mean differences at weeks 8, 16, and 24, with error bars indicating variability in measurements.*

FDA Label Image

Figure 8 (Rivastigmine 09)

A line graph showing LS Mean Change +/- Standard Error over 24 weeks of treatment comparing Rivastigmine Transdermal System 15 cm² and 5 cm². The y-axis represents LS Mean Change with labels for clinical improvement and decline, and the x-axis shows weeks of treatment at 0, 8, 16, and 24 weeks. Data points with error bars indicate the changes for each patch size over time, with statistical values noted for mean differences and p-values at weeks 8, 16, and 24.*

FDA Label Image

Figure A (Rivastigmine 10)

Diagram illustrating the Rivastigmine Transdermal System including its protective packaging pouch and the patch components. The patch consists of adhesive containing medicine, protective liners, and an outside backing, with the Rivastigmine name labeled on the patch surface.*

FDA Label Image

Figure B (Rivastigmine 11)

An instructional diagram illustrating possible application sites for a transdermal patch. It shows shaded areas on the left or right upper arm, left or right side of the chest (front), left or right upper back, and left or right lower back as acceptable locations for patch placement.*

FDA Label Image

Figure C (Rivastigmine 12)

An illustration showing a hand holding a single-use packet of Rivastigmine Transdermal System, 9.5 mg/24h, with scissors cutting the packet open. The packet is labeled with the product name, dosage strength, dosing instructions, and labeler Bryant Ranch Prepack.*

FDA Label Image

Figure D (Rivastigmine 13)

An instructional illustration showing how to handle the Rivastigmine transdermal patch. It depicts fingers peeling away the protective liners to expose the sticky surface of the patch for application.*

FDA Label Image

Figure E (Rivastigmine 14)

An instructional illustration showing application of a Rivastigmine transdermal patch to the upper back. A person uses one hand to place the patch on the skin while the other hand holds the skin surface clear for attachment.*

FDA Label Image

Figure F (Rivastigmine 15)

Illustration showing the correct placement of a transdermal patch on the upper back near the shoulder blade. The image depicts a hand applying a rectangular patch to the skin, indicating the application site for a transdermal medication.*

FDA Label Image

Figure G (Rivastigmine 16)

An instructional illustration showing the application of a Rivastigmine Transdermal System patch to the upper chest. The image depicts one hand peeling the protective backing from the patch with an arrow indicating the peeling direction, while the other hand places the patch onto the skin.*

FDA Label Image

Figure H (Rivastigmine 17)

Illustration showing step-by-step instructions for disposal of a Rivastigmine Transdermal System patch: folding the sticky sides together, sliding the folded patch into the empty pouch saved from the medication, and placing the pouch in the trash while keeping it away from children and pets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.